254 related articles for article (PubMed ID: 31646189)
1. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.
Ko SY; Lee W; Kenny HA; Dang LH; Ellis LM; Jonasch E; Lengyel E; Naora H
Commun Biol; 2019; 2():386. PubMed ID: 31646189
[TBL] [Abstract][Full Text] [Related]
2. Small extracellular vesicle-bound vascular endothelial growth factor secreted by carcinoma-associated fibroblasts promotes angiogenesis in a bevacizumab-resistant manner.
Li J; Liu X; Zang S; Zhou J; Zhang F; Sun B; Qi D; Li X; Kong J; Jin D; Yang X; Luo Y; Lu Y; Lin B; Niu W; Liu T
Cancer Lett; 2020 Nov; 492():71-83. PubMed ID: 32860852
[TBL] [Abstract][Full Text] [Related]
3. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.
Feng Q; Zhang C; Lum D; Druso JE; Blank B; Wilson KF; Welm A; Antonyak MA; Cerione RA
Nat Commun; 2017 Feb; 8():14450. PubMed ID: 28205552
[TBL] [Abstract][Full Text] [Related]
4. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.
Ma S; Mangala LS; Hu W; Bayaktar E; Yokoi A; Hu W; Pradeep S; Lee S; Piehowski PD; Villar-Prados A; Wu SY; McGuire MH; Lara OD; Rodriguez-Aguayo C; LaFargue CJ; Jennings NB; Rodland KD; Liu T; Kundra V; Ram PT; Ramakrishnan S; Lopez-Berestein G; Coleman RL; Sood AK
Cell Rep; 2021 Aug; 36(7):109549. PubMed ID: 34407412
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
6. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
7. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
8. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
9. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
[TBL] [Abstract][Full Text] [Related]
10. Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
Müller-Greven G; Carlin CR; Burgett ME; Ahluwalia MS; Lauko A; Nowacki AS; Herting CJ; Qadan MA; Bredel M; Toms SA; Lathia JD; Hambardzumyan D; Sarkaria JN; Hamerlik P; Gladson CL
Clin Cancer Res; 2017 Nov; 23(22):7059-7071. PubMed ID: 28912141
[No Abstract] [Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
[No Abstract] [Full Text] [Related]
14. Small Extracellular Vesicle-Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.
Wong SWK; Tey SK; Mao X; Fung HL; Xiao ZJ; Wong DKH; Mak LY; Yuen MF; Ng IO; Yun JP; Gao Y; Yam JWP
Adv Sci (Weinh); 2023 Sep; 10(26):e2302677. PubMed ID: 37387563
[TBL] [Abstract][Full Text] [Related]
15. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
16. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.
Simon T; Pinioti S; Schellenberger P; Rajeeve V; Wendler F; Cutillas PR; King A; Stebbing J; Giamas G
Mol Cancer; 2018 Aug; 17(1):132. PubMed ID: 30165850
[TBL] [Abstract][Full Text] [Related]
17. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
18. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
19. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.
Salvador C; Li B; Hansen R; Cramer DE; Kong M; Yan J
Clin Cancer Res; 2008 Feb; 14(4):1239-47. PubMed ID: 18281559
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
